• Zai Lab agreed October 22, 2026, to sell 11,340,000 American depositary shares at USD 22.04 each in a private placement.
• Gross proceeds are expected at USD 249.93 million, with net proceeds of USD 241.17 million.
• Net proceeds will primarily support continued global development of zocilurtatug pelitecan, its DLL3-targeting antibody-drug conjugate.
• The placement represents 113,400,000 underlying ordinary shares, equivalent to 9.06% of enlarged issued share capital.
• Closing is expected October 27, 2026, subject to customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261023-12380653), on October 23, 2026, and is solely responsible for the information contained therein.